Get the content you want anytime you want.

Top 5 Contagion® News Articles for the Week of October 29, 2017


#5: How is Pharma Tackling Antibiotic Resistance? Public Health Watch Report

We are entering the “antibiotic apocalypse.”

At least that’s the phrase used by England’s chief medical officer, Sally Davies, DBE, FMedSci, FRS, to describe the current situation regarding the growing problem of resistance. Dr. Davies made the comment in response to findings, initially presented at the American Society of Microbiology’s annual meeting and published in February in the journal Antimicrobial Agents and Chemotherapy(AAC), that bacteria containing the gene MCR-1 confers resistance to the antibiotic colistin.

As the authors of the AAC paper note, colistin is generally considered an “antibiotic of last resort,” and the discovery of the resistance conferred by the MCR-1 gene could mean that routine surgical procedures and hospitalizations would suddenly become fraught with peril due to the increased risk for resistant infections.

Read the rest of the Public Health Watch Report, here.

#4: FDA Clears 3 Antimicrobial Susceptibility Tests to Guide Appropriate Use of Baxdela

This week, Melinta Therapeutics announced that the US Food and Drug Administration (FDA) has cleared 3 antimicrobial susceptibility tests (ASTs) that will help health care practitioners use its new fluoroquinolone Baxdela, appropriately.

Baxdela (delafloxacin) was recently approved by the FDA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, and is available in both tablet, 450 mg, and intravenous, 300 mg, formulations; it can be dosed for 5 to 14 days, twice daily.

The 3 cleared ASTs are: Hardy Diagnostics’ Delafloxacin Antimicrobial Susceptibility Disk (HardyDisk), Liofilchem Delafloxacin MIC Test Strip (MTS), and Thermo Scientific Sensititre MIC System.

Read more about the ASTs, here.

Big advances in treatment can